Baxalta in hand, Shire dumps drug programs in hunt for $210M in R&D cuts
Now that Shire has closed on its buyout deal for Baxalta, the company has already trimmed a slate of drug development programs as it seeks …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
